How many Rilvegostomig clinical trials are there?

30 Rilvegostomig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 25 are actively recruiting participants.

Are Rilvegostomig clinical trials recruiting in 2026?

Yes — 25 Rilvegostomig trials are actively recruiting in 2026, with 427 U.S. sites across 46 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Rilvegostomig being studied for?

Rilvegostomig is being studied for Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma and 39 more. The trials are grouped by indication on this page.

What phase is Rilvegostomig in?

Rilvegostomig clinical trials span 12 Phase 3, 11 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Rilvegostomig clinical trials?

The lead sponsor across the most Rilvegostomig trials is AstraZeneca, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Rilvegostomig Clinical Trials (2026): 30 Studies for Biliary Tract Cancer & Gastric Cancer

Creator: Hipa.ai Research
Published: 2026-04-21T17:51:12.693Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

30 Rilvegostomig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 21 indications (including Biliary Tract Cancer & Gastric Cancer) and 19,109 total planned enrollment. 12 Phase 3 Rilvegostomig trials and 11 Phase 2 are listed. 27 Rilvegostomig clinical trials are actively recruiting at 427 U.S. sites across 46 states. Most recent activity: NCT04541108 (Dec 2031).

Where to Participate: All Rilvegostomig Trial Sites in the U.S. (427 sites across 46 states)

Every actively recruiting Rilvegostomigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Research Site	Birmingham35233	NCT05775159	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AL	Research Site	Mobile36608	NCT06627647	Map
AK	Research Site	Anchorage99508	NCT06357533	Map
AK	Research Site	Anchorage99508	NCT06764875	Map
AZ	Research Site	Phoenix85054	NCT06627647	Map
AZ	Research Site	Phoenix85054	NCT06764875	Map
AZ	Research Site	Phoenix85054	NCT06921785	Map
AZ	Research Site	Phoenix85054	NCT06996782	Map
AZ	Research Site	Scottsdale85259	NCT06467357	Map
AZ	Research Site	Tucson85719	NCT06357533	Map
AZ	Research Site	Tucson85724	NCT06692738	Map
AR	Research Site	Little Rock72205	NCT05061550	Map
AR	Research Site	Little Rock72205	NCT06357533	Map
AR	Research Site	Little Rock72205	NCT06989112	Map
AR	Research Site	Springdale72762	NCT06357533	Map
AR	Research Site	Springdale72762	NCT06692738	Map
CA	Research Site	Anaheim92801	NCT06357533	Map
CA	Research Site	Anaheim92801	NCT06627647	Map
CA	Research Site	Anaheim92801	NCT06692738	Map
CA	Research Site	Beverly Hills90211	NCT06357533	Map
CA	Research Site	Beverly Hills90211	NCT06627647	Map
CA	Research Site	Beverly Hills90211	NCT06692738	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	Research Site	Duarte91010	NCT06764875	Map
CA	Research Site	Duarte91010	NCT07221253	Map
CA	Research Site	Fountain Valley92708	NCT06357533	Map
CA	Research Site	Fullerton92835	NCT06467357	Map
CA	Research Site	La Jolla92093	NCT06467357	Map
CA	Research Site	La Jolla92037	NCT06764875	Map
CA	Research Site	La Jolla92037	NCT06989112	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	Research Site	Loma Linda92354	NCT06692738	Map
CA	Research Site	Los Alamitos90720	NCT06692738	Map
CA	Research Site	Los Angeles90095	NCT05489211	Map
CA	Research Site	Los Angeles90017	NCT05702229	Map
CA	Research Site	Los Angeles90089	NCT05775159	Map
CA	Research Site	Los Angeles90095	NCT05061550	Map
CA	Research Site	Los Angeles90017	NCT06467357	Map
CA	Research Site	Los Angeles90089	NCT06467357	Map
CA	Research Site	Los Angeles90089	NCT06764875	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	Research Site	Orange92868	NCT04686305	Map
CA	Research Site	Orange92868	NCT05775159	Map
CA	Research Site	Palo Alto94304	NCT06921785	Map
CA	Research Site	Redlands92373	NCT06627647	Map
CA	Research Site	Redlands92373	NCT06692738	Map
CA	UC Davis	Sacramento95817	NCT06366451	Map
CA	Research Site	San Diego92123	NCT06627647	Map
CA	Research Site	San Francisco94143	NCT06467357	Map
CA	Research Site	San Francisco94121	NCT06627647	Map
CA	Research Site	San Francisco94121	NCT06692738	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	Research Site	Santa Monica90404	NCT05123482	Map
CA	Research Site	Santa Monica90404	NCT06764875	Map
CA	Research Site	Santa Rosa95403	NCT05489211	Map
CA	Research Site	Santa Rosa95403	NCT05123482	Map
CA	Research Site	Santa Rosa95403	NCT06627647	Map
CA	Research Site	Santa Rosa95403	NCT06996782	Map
CA	Research Site	Solvang93463	NCT06764875	Map
CA	Research Site	Upland91786	NCT06764875	Map
CA	Research Site	Walnut Creek94598	NCT06627647	Map
CA	Research Site	Walnut Creek94598	NCT06692738	Map
CA	Research Site	Walnut Creek94598	NCT06764875	Map
CO	Research Site	Aurora80045	NCT06764875	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CO	Research Site	Lone Tree80124	NCT06627647	Map
CT	Research Site	Farmington06030	NCT06868277	Map
CT	Research Site	New Haven06510	NCT05061550	Map
CT	Research Site	New Haven06520	NCT06921785	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
CT	Research Site	Stamford06902	NCT06627647	Map
CT	Research Site	West Haven06516	NCT06627647	Map
CT	Research Site	West Haven06516	NCT06692738	Map
DE	Research Site	Newark19713	NCT06627647	Map
DE	Research Site	Newark19713	NCT06692738	Map
DE	Research Site	Newark19713	NCT06868277	Map
DE	Research Site	Newark19713	NCT06921785	Map
DE	Research Site	Newark19713	NCT07069712	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
DC	Research Site	Washington D.C.20007	NCT07069712	Map
FL	Research Site	Bay Pines33744	NCT06627647	Map
FL	Research Site	Bay Pines33744	NCT06692738	Map
FL	Research Site	Bay Pines33744	NCT06868277	Map
FL	Research Site	Clearwater33756	NCT06868277	Map
FL	Research Site	Clermont34711	NCT06357533	Map
FL	Research Site	Fort Lauderdale33308	NCT06627647	Map
FL	Research Site	Fort Lauderdale33308	NCT06692738	Map
FL	Research Site	Fort Myers33901	NCT06467357	Map
FL	Research Site	Fort Myers33901	NCT06989112	Map
FL	Research Site	Gainesville32608	NCT06357533	Map
FL	Research Site	Gainesville32608	NCT06692738	Map
FL	Research Site	Jacksonville32224	NCT06467357	Map
FL	Research Site	Jacksonville32224	NCT06627647	Map
FL	Research Site	Jacksonville32224	NCT06692738	Map
FL	Research Site	Jacksonville32224	NCT06764875	Map
FL	Research Site	Jacksonville32224	NCT06921785	Map
FL	Research Site	Jacksonville32224	NCT06996782	Map
FL	Research Site	Miami33125	NCT06627647	Map
FL	Research Site	Miami Beach33140	NCT06357533	Map
FL	Research Site	Miami Beach33140	NCT06989112	Map
FL	Research Site	Ocala34474	NCT06627647	Map
FL	Research Site	Orange City32763	NCT06357533	Map
FL	Research Site	Orlando32806	NCT06357533	Map
FL	Research Site	Orlando32806	NCT06764875	Map
FL	Research Site	St. Petersburg33705	NCT06467357	Map
FL	Research Site	St. Petersburg33709	NCT06627647	Map
FL	Research Site	St. Petersburg33705	NCT06868277	Map
FL	Research Site	St. Petersburg33705	NCT06989112	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
FL	Research Site	Tampa33612	NCT06989112	Map
FL	Research Site	West Palm Beach33401	NCT06357533	Map
FL	Research Site	West Palm Beach33401	NCT06467357	Map
FL	Research Site	West Palm Beach33401	NCT06989112	Map
GA	Research Site	Athens30607	NCT06692738	Map
GA	Research Site	Atlanta30318	NCT06357533	Map
GA	Research Site	Atlanta30322	NCT06357533	Map
GA	Research Site	Atlanta30309	NCT06467357	Map
GA	Research Site	Atlanta30318	NCT06921785	Map
GA	Research Site	Atlanta30318	NCT07098338	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
GA	Research Site	Augusta30912	NCT06989112	Map
GA	Research Site	Marietta30060	NCT06764875	Map
GA	Research Site	Marietta30060	NCT06868277	Map
GA	Research Site	Marietta30060	NCT07221253	Map
ID	Research Site	Boise83712	NCT06627647	Map
ID	Research Site	Boise83712	NCT06692738	Map
IL	Research Site	Arlington Heights60005	NCT06989112	Map
IL	Research Site	Chicago60637	NCT05061550	Map
IL	Research Site	Chicago60612	NCT06467357	Map
IL	Research Site	Chicago60637	NCT06627647	Map
IL	Research Site	Chicago60637	NCT06692738	Map
IL	Research Site	Chicago60612	NCT06764875	Map
IL	Research Site	Chicago60612	NCT06868277	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	Research Site	Decatur62526	NCT06627647	Map
IL	Research Site	Decatur62526	NCT06692738	Map
IL	Research Site	Decatur62526	NCT06868277	Map
IL	Research Site	Evanston60201	NCT06989112	Map
IL	Research Site	Hinsdale60521	NCT06357533	Map
IL	Research Site	Hinsdale60521	NCT06627647	Map
IL	Research Site	Hinsdale60521	NCT06692738	Map
IL	Research Site	Hinsdale60521	NCT06764875	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IL	Research Site	Niles60714	NCT06467357	Map
IL	Research Site	Niles60714	NCT06764875	Map
IL	Research Site	Quincy62305	NCT06627647	Map
IL	Research Site	Quincy62301	NCT06692738	Map
IN	Research Site	Noblesville46062	NCT06357533	Map
IA	Research Site	Des Moines50309	NCT06868277	Map
IA	Research Site	Waterloo50702	NCT06627647	Map
IA	Research Site	Waterloo50702	NCT06692738	Map
KS	Research Site	Fairway66205	NCT07069712	Map
KS	Research Site	Kansas City66103	NCT05775159	Map
KS	Research Site	Leawood66209	NCT06868277	Map
KY	Research Site	Lexington40509	NCT06627647	Map
KY	Research Site	Lexington40509	NCT06692738	Map
KY	Research Site	Louisville40207	NCT06627647	Map
KY	Research Site	Louisville40202	NCT06692738	Map
KY	Research Site	Louisville40207	NCT06692738	Map
KY	Research Site	Louisville40217	NCT06764875	Map
KY	Research Site	Owensboro42303	NCT06868277	Map
LA	Research Site	Baton Rouge70817	NCT05702229	Map
LA	Research Site	Baton Rouge70808	NCT06692738	Map
LA	Research Site	Shreveport71103	NCT06627647	Map
LA	Research Site	Shreveport71105	NCT06627647	Map
LA	Research Site	Shreveport71103	NCT06692738	Map
LA	Research Site	Shreveport71105	NCT06692738	Map
LA	Research Site	Shreveport71103	NCT06989112	Map
ME	Research Site	Scarborough04074	NCT06692738	Map
ME	Research Site	South Portland04106	NCT06627647	Map
MD	Research Site	Annapolis21401	NCT06357533	Map
MD	Research Site	Baltimore21287	NCT04686305	Map
MD	Research Site	Baltimore21287	NCT04379596	Map
MD	Research Site	Baltimore21231	NCT05061550	Map
MD	Research Site	Baltimore21231	NCT05123482	Map
MD	Research Site	Baltimore21202	NCT06627647	Map
MD	Research Site	Baltimore21202	NCT06692738	Map
MD	Research Site	Baltimore21201	NCT06989112	Map
MD	Research Site	Bethesda20817	NCT06692738	Map
MD	Research Site	Bethesda20817	NCT06868277	Map
MD	Research Site	Frederick21702	NCT06868277	Map
MD	Research Site	Silver Spring20904	NCT06764875	Map
MD	Research Site	Silver Spring20910	NCT06868277	Map
MD	Research Site	Towson21204	NCT06467357	Map
MD	Research Site	Towson21204	NCT06868277	Map
MA	Research Site	Boston02215	NCT04379596	Map
MA	Research Site	Boston02215	NCT05061550	Map
MA	Research Site	Boston02215	NCT05123482	Map
MA	Research Site	Boston02114	NCT06357533	Map
MA	Research Site	Boston02215	NCT06357533	Map
MA	Research Site	Boston02111	NCT06989112	Map
MI	Research Site	Dearborn48126	NCT06357533	Map
MI	Research Site	Detroit48202	NCT06692738	Map
MI	Research Site	Farmington Hills48334	NCT06357533	Map
MI	Research Site	Grand Rapids49503	NCT05489211	Map
MI	Research Site	Grand Rapids49503	NCT05702229	Map
MI	Research Site	Grand Rapids49503	NCT06357533	Map
MI	Research Site	Grand Rapids49503	NCT06467357	Map
MI	Research Site	Grand Rapids49503	NCT06627647	Map
MI	Research Site	Grand Rapids49503	NCT06692738	Map
MI	Research Site	Grand Rapids49503	NCT06764875	Map
MI	Research Site	Grand Rapids49503	NCT06921785	Map
MI	Research Site	Grand Rapids49546	NCT07115043	Map
MI	Research Site	Grand Rapids49503	NCT07431281	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MI	Research Site	North Shores49444	NCT07069712	Map
MN	Research Site	Burnsville55337	NCT06764875	Map
MN	Research Site	Duluth55802	NCT06692738	Map
MN	Research Site	Minneapolis55455	NCT06989112	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Research Site	Rochester55905	NCT06467357	Map
MN	Research Site	Rochester55905	NCT06627647	Map
MN	Research Site	Rochester55905	NCT06692738	Map
MN	Research Site	Rochester55905	NCT06921785	Map
MN	Research Site	Rochester55905	NCT06996782	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MN	Research Site	Saint Paul55102	NCT06627647	Map
MS	Research Site	Hattiesburg39401	NCT06357533	Map
MS	Research Site	Jackson39216	NCT06989112	Map
MO	Research Site	Bridgeton63044	NCT06627647	Map
MO	Research Site	Bridgeton63044	NCT06692738	Map
MO	Research Site	Bridgeton63044	NCT06868277	Map
MO	Research Site	Kansas City64132	NCT06357533	Map
MO	Research Site	Kansas City64132	NCT06467357	Map
MO	Research Site	Kansas City64108	NCT06692738	Map
MO	Research Site	St Louis63110	NCT05123482	Map
MO	Research Site	St Louis63110	NCT06467357	Map
MO	Research Site	St Louis63108	NCT06764875	Map
MO	Research Site	St Louis63141	NCT06989112	Map
MO	Research Site	St Louis63110	NCT07115043	Map
MO	Research Site	St Louis63110	NCT07431281	Map
NE	Research Site	Grand Island68803	NCT06357533	Map
NE	Research Site	Lincoln68506	NCT06627647	Map
NE	Research Site	Lincoln68506	NCT06692738	Map
NE	Research Site	Lincoln68506	NCT06868277	Map
NE	Research Site	Omaha68124	NCT05061550	Map
NE	Research Site	Omaha68130	NCT06357533	Map
NV	Research Site	Las Vegas89102	NCT06357533	Map
NV	Research Site	Reno89502	NCT06764875	Map
NH	Research Site	Lebanon03756	NCT06989112	Map
NJ	Research Site	Camden08103	NCT06627647	Map
NJ	Research Site	Camden08103	NCT06692738	Map
NJ	Research Site	East Brunswick08816	NCT05489211	Map
NJ	Research Site	East Brunswick08816	NCT07431281	Map
NJ	Research Site	New Brunswick08901	NCT06921785	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NM	Research Site	Albuquerque87109	NCT05489211	Map
NM	Research Site	Albuquerque87109	NCT05123482	Map
NM	Research Site	Santa Fe87505	NCT06764875	Map
NM	Research Site	Santa Fe87505	NCT07221253	Map
NY	Research Site	Buffalo14263	NCT05061550	Map
NY	Research Site	Buffalo14221	NCT06627647	Map
NY	Research Site	Buffalo14221	NCT06692738	Map
NY	Research Site	Buffalo14215	NCT06868277	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	Research Site	Commack11725	NCT05489211	Map
NY	Research Site	Commack11725	NCT05123482	Map
NY	Research Site	East Syracuse13057	NCT06692738	Map
NY	Research Site	East Syracuse13057	NCT06868277	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	Research Site	New York10065	NCT04379596	Map
NY	Research Site	New York10065	NCT05702229	Map
NY	Research Site	New York10065	NCT05775159	Map
NY	Research Site	New York10021	NCT06764875	Map
NY	Research Site	New York10029	NCT06921785	Map
NY	Research Site	New York10065	NCT06989112	Map
NY	Research Site	New York10065	NCT07069712	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Research Site	Stony Brook11794	NCT06357533	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center	The Bronx10467	NCT06366451	Map
NY	Research Site	Westbury11590	NCT06627647	Map
NY	Research Site	Westbury11590	NCT06692738	Map
NY	Research Site	Westbury11590	NCT06868277	Map
NY	Research Site	White Plains10601	NCT06467357	Map
NC	University of North Carolina	Chapel Hill27599	NCT06366451	Map
NC	Research Site	Charlotte28204	NCT05123482	Map
NC	Research Site	Charlotte28204	NCT06989112	Map
NC	Research Site	Greenville27834	NCT06357533	Map
NC	Research Site	Huntersville28078	NCT07161414	Map
NC	Research Site	Salisbury28144	NCT06357533	Map
NC	Research Site	Wilson27893	NCT06692738	Map
NC	Research Site	Winston-Salem27103	NCT06989112	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
ND	Research Site	Grand Forks58201	NCT06692738	Map
OH	Research Site	Canton44710	NCT06627647	Map
OH	Research Site	Cincinnati45219	NCT05489211	Map
OH	Research Site	Cincinnati45219	NCT06357533	Map
OH	Research Site	Cincinnati45267	NCT06692738	Map
OH	Research Site	Cincinnati45220	NCT06764875	Map
OH	Research Site	Cincinnati45220	NCT06989112	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	Research Site	Cleveland44195	NCT05061550	Map
OH	Research Site	Cleveland44195	NCT06467357	Map
OH	Research Site	Cleveland44106	NCT06996782	Map
OH	Research Site	Columbus43219	NCT05489211	Map
OH	Research Site	Columbus43210	NCT06467357	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OH	Research Site	Maumee43537	NCT06357533	Map
OH	Research Site	Toledo43623	NCT06357533	Map
OR	Research Site	Eugene97401	NCT06989112	Map
OR	Research Site	Medford97504	NCT06627647	Map
OR	Research Site	Medford97504	NCT06692738	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
OR	Research Site	Salem97301	NCT06627647	Map
OR	Research Site	Salem97301	NCT06692738	Map
PA	Research Site	Fountain Hill18015	NCT06868277	Map
PA	Research Site	Hershey17033	NCT06692738	Map
PA	Research Site	Philadelphia19104	NCT06868277	Map
PA	Research Site	Philadelphia19111	NCT06989112	Map
PA	University of Pennsylvania	Philadelphia19107	NCT06366451	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	Research Site	Pittsburgh15212	NCT05061550	Map
PA	Research Site	Pittsburgh15213	NCT05123482	Map
PA	Research Site	Pittsburgh15232	NCT06921785	Map
PA	Research Site	Pittsburgh15224	NCT06989112	Map
PA	Research Site	Pittsburgh15232	NCT07115043	Map
PA	Research Site	York17403	NCT06627647	Map
PA	Research Site	York17403	NCT06692738	Map
RI	Research Site	Providence02905	NCT06989112	Map
RI	Research Site	Providence02903	NCT06996782	Map
SC	Medical University of South Carolina	Charleston29407	NCT06366451	Map
SC	Research Site	Charleston29425	NCT06989112	Map
SC	Sarah Cannon Medical Center	Charleston29406	NCT06366451	Map
SC	Research Site	Greenville29607	NCT06357533	Map
SC	Research Site	Greenville29605	NCT06467357	Map
SD	Research Site	Pierre57501	NCT06627647	Map
SD	Research Site	Sioux Falls57105	NCT06357533	Map
SD	Research Site	Sioux Falls57105	NCT06627647	Map
SD	Research Site	Sioux Falls57105	NCT06692738	Map
SD	Research Site	Sioux Falls57105	NCT06989112	Map
SD	Research Site	Sioux Falls57105	NCT07221253	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
TN	Research Site	Chattanooga37404	NCT05061550	Map
TN	Research Site	Chattanooga37404	NCT06627647	Map
TN	Research Site	Chattanooga37404	NCT06692738	Map
TN	Research Site	Knoxville37909	NCT06764875	Map
TN	Research Site	Memphis38120	NCT05061550	Map
TN	Research Site	Nashville37203	NCT05489211	Map
TN	Research Site	Nashville37203	NCT05061550	Map
TN	Research Site	Nashville37232	NCT05061550	Map
TN	Research Site	Nashville37203	NCT06627647	Map
TN	Research Site	Nashville37203	NCT06692738	Map
TN	Research Site	Nashville37203	NCT07431281	Map
TX	Research Site	Amarillo79124	NCT06921785	Map
TX	Research Site	Austin78705	NCT06921785	Map
TX	Research Site	Austin78758	NCT06989112	Map
TX	Research Site	Dallas75246	NCT06467357	Map
TX	Research Site	Dallas75246	NCT06764875	Map
TX	Research Site	Fort Worth76104	NCT06357533	Map
TX	Research Site	Fort Worth76104	NCT06467357	Map
TX	Research Site	Fort Worth76104	NCT06627647	Map
TX	Research Site	Fort Worth76104	NCT06692738	Map
TX	Research Site	Fort Worth76104	NCT06989112	Map
TX	Research Site	Houston77030	NCT05489211	Map
TX	Research Site	Houston77030	NCT04686305	Map
TX	Research Site	Houston77090	NCT04379596	Map
TX	Research Site	Houston77030	NCT05061550	Map
TX	Research Site	Houston77090	NCT05061550	Map
TX	Research Site	Houston77030	NCT05123482	Map
TX	Research Site	Houston77030	NCT06357533	Map
TX	Research Site	Houston77030	NCT06467357	Map
TX	Research Site	Houston77030	NCT06921785	Map
TX	Research Site	Houston77030	NCT06989112	Map
TX	Research Site	Houston77030	NCT07115043	Map
TX	Research Site	Irving75063	NCT06627647	Map
TX	Research Site	Kingwood77339	NCT06357533	Map
TX	Research Site	Kingwood77339	NCT06627647	Map
TX	Research Site	Kingwood77339	NCT06692738	Map
TX	Research Site	Lubbock79410	NCT06692738	Map
TX	Research Site	Odessa79761	NCT06357533	Map
TX	Research Site	Palestine75801	NCT06627647	Map
TX	Research Site	Round Rock78665	NCT06627647	Map
TX	Research Site	Round Rock78665	NCT06692738	Map
TX	Research Site	San Antonio78240	NCT06921785	Map
TX	Research Site	San Antonio78240	NCT06989112	Map
TX	Research Site	San Antonio78229	NCT07115043	Map
TX	Research Site	San Antonio78229	NCT07161414	Map
TX	Research Site	Tyler75702	NCT06921785	Map
TX	Research Site	Tyler75708	NCT06996782	Map
TX	Research Site	Webster77598	NCT06764875	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
VA	Research Site	Arlington22201	NCT06921785	Map
VA	Research Site	Charlottesville22908	NCT06764875	Map
VA	Research Site	Charlottesville22908	NCT06989112	Map
VA	Research Site	Fairfax22031	NCT04686305	Map
VA	Research Site	Fairfax22031	NCT05061550	Map
VA	Research Site	Fairfax22031	NCT06467357	Map
VA	Research Site	Fairfax22031	NCT06627647	Map
VA	Research Site	Fairfax22031	NCT06692738	Map
VA	Research Site	Fairfax22031	NCT06764875	Map
VA	Research Site	Fairfax22031	NCT07098338	Map
VA	Research Site	Fairfax22031	NCT07115043	Map
VA	Research Site	Fairfax22031	NCT07161414	Map
VA	Research Site	Fort Belvoir22060	NCT06357533	Map
VA	Research Site	Fredericksburg22408	NCT06692738	Map
VA	Research Site	Leesburg20176	NCT06357533	Map
VA	Research Site	Norfolk23502	NCT06627647	Map
VA	Research Site	Richmond23230	NCT06357533	Map
VA	Research Site	Roanoke24014	NCT06627647	Map
VA	Research Site	Salem24153	NCT06921785	Map
WA	Research Site	Edmonds98026	NCT05061550	Map
WA	Research Site	Olympia98506	NCT06692738	Map
WA	Research Site	Seattle98104	NCT05061550	Map
WA	Research Site	Seattle98101	NCT06627647	Map
WA	Research Site	Seattle98101	NCT06692738	Map
WA	Research Site	Silverdale98383	NCT06627647	Map
WA	Research Site	Spokane99208	NCT06627647	Map
WA	Research Site	Spokane99208	NCT06692738	Map
WA	Research Site	Tacoma98405	NCT06357533	Map
WA	Research Site	Tacoma98405	NCT06627647	Map
WA	Research Site	Tacoma98405	NCT06692738	Map
WA	Research Site	Vancouver98684	NCT06357533	Map
WA	Research Site	Wenatchee98801	NCT06357533	Map
WV	Research Site	Charleston25304	NCT06764875	Map
WV	Research Site	Charleston25304	NCT06868277	Map
WV	Research Site	Morgantown26506	NCT06868277	Map
WI	Research Site	Appleton54911	NCT06357533	Map
WI	Research Site	Madison53792	NCT05489211	Map
WI	Research Site	Madison53792	NCT06989112	Map
WI	Research Site	Milwaukee53226	NCT06921785	Map

Rilvegostomig clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	not yet recruiting	Total
Early P1	1	1		2
P1	2			2
P1/P2	3			3
P2	9		2	11
P3	10	2		12

Recruiting Rilvegostomig clinical trials (27)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT01042379	I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	Breast Neoplasms	5,000	Mar 2010
NCT07431281	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2	P3	Gastric Cancer	2,130	Feb 2026
NCT06989112	DE-01DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer	P3	Endometrial Cancer	600	Mar 2025
NCT06764875	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer	P3	HER2-positive Gastric Cancer	840	Mar 2025
NCT06868277	ARTEMIDELung04A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer	P3	Carcinoma, Non-Small Cell Lung	830	Apr 2025
NCT05061550	NeoCOAST-2Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer	P2	Non-small Cell Lung Cancer	630	Apr 2022
NCT06627647	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	P3	Non-squamous Non-small Cell Lung Cancer	878	Nov 2024
NCT06921785	ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	Hepatocellular Carcinoma	1,220	May 2025
NCT06357533	TROPION-Lung10Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations	P3	Non-Small Cell Lung Cancer	675	Apr 2024
NCT06692738	NSCLCA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	P3	Non-small Cell Lung Cancer	880	Nov 2024
NCT07115043	A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors	P1/P2	Melanoma	60	Jul 2025
NCT07161414	ARTEMIDE-subQA Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy	P1	Advanced Solid Tumors	40	Nov 2025
NCT07221253	AB02A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)	P3	Biliary Tract Cancer	1,100	Dec 2025
NCT06630130	Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer	P2	Stomach Neoplasms	50	Jan 2025
NCT05702229	Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	P2	Gastric Cancer	163	Jan 2023
NCT06467357	DESTINY-BTC01Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer	P3	Biliary Tract Cancer	620	Aug 2024
NCT07128290	PEHRICCAPErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma	P2	Intrahepatic Cholangiocarcinoma (Icc)	49	Oct 2025
NCT07098338	LIBRAA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)	P2	Non-Small Cell Lung Cancer	278	Aug 2025
NCT06996782	ALTAIRA Platform Study in Non-Small Cell Lung Cancer (NSCLC)	P1/P2	Advanced or Metastatic Non-small Cell Lung Cancer	152	Nov 2025
NCT06569225	NEOLANGIOGemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA	P2	Cholangiocarcinoma Resectable	40	Dec 2024
NCT07069712	A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma	P2	Gastroesophageal Adenocarcinoma	100	Jul 2025
NCT05775159	Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	P2	Hepatocellular Carcinoma	294	Apr 2023
NCT05489211	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	P2	Endometrial Cancer	454	Sep 2022
NCT05123482	A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies	P1/P2	Breast Cancer	460	Oct 2021
NCT04686305	DL03Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	P1	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	304	Mar 2021
NCT04379596	DG-03Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)	P2	Gastric Cancer	450	Jun 2020
NCT06366451	NCT04541108PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC	Early P1	Head and Neck Squamous Cell Carcinoma	15	May 2024

Rilvegostomig clinical trials by indication

Gastric Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT07431281	—	P3	recruiting	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT05702229	—	P2	recruiting	Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04379596	DG-03	P2	recruiting	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Biliary Tract Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06109779	—	P3	active not recruiting	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT07221253	AB02	P3	recruiting	A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT06467357	DESTINY-BTC01	P3	recruiting	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Non-small Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05061550	NeoCOAST-2	P2	recruiting	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT06692738	NSCLC	P3	recruiting	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06564844	TROPION-Lung12	P3	active not recruiting	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Non-Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06357533	TROPION-Lung10	P3	recruiting	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT07098338	LIBRA	P2	recruiting	A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06921785	ARTEMIDE-HCC01	P3	recruiting	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT05775159	—	P2	recruiting	Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Endometrial Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06989112	DE-01	P3	recruiting	DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT05489211	—	P2	recruiting	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT07161414	ARTEMIDE-subQ	P1	recruiting	A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

Advanced or Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06996782	ALTAIR	P1/P2	recruiting	A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Intrahepatic Cholangiocarcinoma (Icc) (1)

NCT	Acronym	Phase	Status	Title
NCT07128290	PEHRICCA	P2	not yet recruiting	PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT07115043	—	P1/P2	recruiting	A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Gastroesophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07069712	—	P2	recruiting	A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Carcinoma, Non-Small Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT06868277	ARTEMIDELung04	P3	recruiting	A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

HER2-positive Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06764875	—	P3	recruiting	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Stomach Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06630130	—	P2	recruiting	Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Cholangiocarcinoma Resectable (1)

NCT	Acronym	Phase	Status	Title
NCT06569225	NEOLANGIO	P2	not yet recruiting	Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

Non-squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06627647	—	P3	recruiting	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06366451	NCT04541108	Early P1	recruiting	PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05123482	—	P1/P2	recruiting	A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04541108	—	Early P1	active not recruiting	Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04686305	DL03	P1	recruiting	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01042379	I-SPY	P2	recruiting	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Rilvegostomig pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
DE-01	NCT06989112	P3	recruiting	Endometrial Cancer	600	—
ARTEMIDELung04	NCT06868277	P3	recruiting	Carcinoma, Non-Small Cell Lung	830	—
ARTEMIDE-HCC01	NCT06921785	P3	recruiting	Hepatocellular Carcinoma	1,220	—
TROPION-Lung10	NCT06357533	P3	recruiting	Non-Small Cell Lung Cancer	675	—
NSCLC	NCT06692738	P3	recruiting	Non-small Cell Lung Cancer	880	—
AB02	NCT07221253	P3	recruiting	Biliary Tract Cancer	1,100	—
DESTINY-BTC01	NCT06467357	P3	recruiting	Biliary Tract Cancer	620	—
TROPION-Lung12	NCT06564844	P3	active not recruiting	Non-small Cell Lung Cancer	25	—
I-SPY	NCT01042379	P2	recruiting	Breast Neoplasms	5,000	—
NeoCOAST-2	NCT05061550	P2	recruiting	Non-small Cell Lung Cancer	630	—
PEHRICCA	NCT07128290	P2	not yet recruiting	Intrahepatic Cholangiocarcinoma (Icc)	49	—
LIBRA	NCT07098338	P2	recruiting	Non-Small Cell Lung Cancer	278	—
NEOLANGIO	NCT06569225	P2	not yet recruiting	Cholangiocarcinoma Resectable	40	—
DG-03	NCT04379596	P2	recruiting	Gastric Cancer	450	—

All Rilvegostomig trials (30)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT04541108		Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies	Early P1	active not recruiting	15	Presage Biosciences	Jul 2021
NCT01042379	I-SPY	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	recruiting	5,000	QuantumLeap Healthcare Collaborative	Mar 2010
NCT07431281		Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2	P3	recruiting	2,130	AstraZeneca	Feb 2026
NCT06989112	DE-01	DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer	P3	recruiting	600	AstraZeneca	Mar 2025
NCT06764875		A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer	P3	recruiting	840	AstraZeneca	Mar 2025
NCT06868277	ARTEMIDELung04	A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer	P3	recruiting	830	AstraZeneca	Apr 2025
NCT05061550	NeoCOAST-2	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer	P2	recruiting	630	AstraZeneca	Apr 2022
NCT06109779		Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)	P3	active not recruiting	757	AstraZeneca	Dec 2023
NCT06627647		A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	P3	recruiting	878	AstraZeneca	Nov 2024
NCT06921785	ARTEMIDE-HCC01	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	recruiting	1,220	AstraZeneca	May 2025
NCT06357533	TROPION-Lung10	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations	P3	recruiting	675	AstraZeneca	Apr 2024
NCT06692738	NSCLC	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	P3	recruiting	880	AstraZeneca	Nov 2024
NCT07115043		A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors	P1/P2	recruiting	60	AstraZeneca	Jul 2025
NCT07161414	ARTEMIDE-subQ	A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy	P1	recruiting	40	AstraZeneca	Nov 2025
NCT07221253	AB02	A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)	P3	recruiting	1,100	AstraZeneca	Dec 2025
NCT06630130		Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer	P2	recruiting	50	Jeeyun Lee	Jan 2025
NCT05702229		Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	P2	recruiting	163	AstraZeneca	Jan 2023
NCT06467357	DESTINY-BTC01	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer	P3	recruiting	620	AstraZeneca	Aug 2024
NCT07128290	PEHRICCA	PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma	P2	not yet recruiting	49	Federation Francophone de Cancerologie Digestive	Oct 2025
NCT07098338	LIBRA	A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)	P2	recruiting	278	AstraZeneca	Aug 2025
NCT06996782	ALTAIR	A Platform Study in Non-Small Cell Lung Cancer (NSCLC)	P1/P2	recruiting	152	AstraZeneca	Nov 2025
NCT06569225	NEOLANGIO	Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA	P2	not yet recruiting	40	University Health Network, Toronto	Dec 2024
NCT07069712		A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma	P2	recruiting	100	AstraZeneca	Jul 2025
NCT05775159		Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	P2	recruiting	294	AstraZeneca	Apr 2023
NCT05489211		Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	P2	recruiting	454	AstraZeneca	Sep 2022
NCT05123482		A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies	P1/P2	recruiting	460	AstraZeneca	Oct 2021
NCT06564844	TROPION-Lung12	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features	P3	active not recruiting	25	AstraZeneca	Oct 2024
NCT04686305	DL03	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	P1	recruiting	304	AstraZeneca	Mar 2021
NCT04379596	DG-03	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)	P2	recruiting	450	AstraZeneca	Jun 2020
NCT06366451	NCT04541108	PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC	Early P1	recruiting	15	Presage Biosciences	May 2024

Rilvegostomig clinical trials: frequently asked questions

How many Rilvegostomig clinical trials are there?: 30 Rilvegostomig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 25 are actively recruiting participants.
Are Rilvegostomig clinical trials recruiting in 2026?: Yes — 25 Rilvegostomig trials are actively recruiting in 2026, with 427 U.S. sites across 46 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Rilvegostomig being studied for?: Rilvegostomig is being studied for Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma and 39 more. The trials are grouped by indication on this page.
What phase is Rilvegostomig in?: Rilvegostomig clinical trials span 12 Phase 3, 11 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Rilvegostomig clinical trials?: The lead sponsor across the most Rilvegostomig trials is AstraZeneca, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Rilvegostomigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Rilvegostomig overview